Glutathione S transferase deficiency and passive smoking increase childhood asthma

M Kabesch, C Hoefler, D Carr, W Leupold, S K Weiland, E von Mutius

Background: It has been suggested that the genetically determined deficiency of glutathione S transferase (GST) enzymes involved in the detoxification of environmental tobacco smoke (ETS) components may contribute to the development of asthma.

Methods: A large population of German schoolchildren (n = 3054) was genotyped for deficiencies of the GST isoforms M1 and T1. The association between GSTM1 and GSTT1 genotypes and asthma as well as atopy was investigated with respect to current and in utero ETS exposure.

Results: In children lacking the GSTM1 allele who were exposed to current ETS the risk for current asthma (OR 5.5, 95% CI 1.6 to 18.6) and asthma symptoms such as wheeze ever (OR 2.8, 95% CI 1.3 to 6.0), current wheezing (OR 4.7, 95% CI 1.8 to 12.6) and shortness of breath (OR 8.9, 95% CI 2.1 to 38.4) was higher than in GSTM1 positive individuals without ETS exposure. Hints of an interaction between ETS exposure and GSTM1 deficiency were identified. In utero smoke exposure in GSTT1 deficient children was associated with significant decrements in lung function compared with GSTT1 positive children not exposed to ETS.

Conclusions: GSTM1 and GSTT1 deficiency may increase the adverse health effects of in utero and current smoke exposure.

Asthma and allergies have become some of the most frequent chronic diseases in children in western countries. There is evidence that a genetic predisposition influences the ability of the immune system to interact with the environment. In asthma a genetic predisposition may also alter the capability of the airway to protect itself against inhaled toxic substances from the environment. This may lead to airway inflammation, damage the airway epithelium, and diminish the barrier function of the airway.

Numerous studies have reported an association between environmental tobacco smoke (ETS) exposure and respiratory diseases: Maternal smoking during pregnancy and early childhood is associated with impaired lung growth and diminished lung function and, in asthmatic children, parental smoking increases symptoms and the frequency of asthma attacks.

ETS consists of a complex mixture of gases and particles including more than 4000 different chemicals. The metabolism and detoxification of tobacco smoke components are essential mechanisms to minimise the toxic effects of ETS. In humans glutathione S transferases (GSTs) are involved in a broad range of these detoxification processes. Four cytosolic classes of GSTs have been identified—Alpha (A), Mu (M), Pi (P), and Theta (T)—with each of these major classes containing subclasses. For example, five different genes code for Mu class GSTs (GSTM1–M5). Located mainly in the cytosol, GST enzymes catalyse the conjugation of electrophilic substrates to glutathione, but also play an important role in peroxidase and isomerase activities. GSTs facilitate responses to oxidative stress reactions, are involved in major detoxification pathways of polycyclic aromatic hydrocarbons, and detoxify benzo[a]pyrene, a carcinogenic found in tobacco smoke. It is therefore likely that genetic alterations of GST enzymes change the ability of the airways to deal with toxic substances and influence airway inflammation and lung development. Thus, GST genes have been suggested as candidate genes for asthma.

Genetic studies of the GST system have mainly focused on the genes GSTM1 (chromosome 1p13.3) and GSTT1 (22q11.2) which code for the enzymes GSTM and GSTT, respectively. Whole gene deletions of GSTM1 and GSTT1 resulting in a complete loss of function of the respective enzyme are common in white populations. Previous studies on the effects of genetic alterations in GSTM1 and GSTT1 have reported associations between these genes and asthma, bronchial hyperresponsiveness, and lung development. We genotyped 3054 German children for the genetically determined deficiency of GSTM1 and GSTT1 and investigated the interaction of both genetic variants with in utero and current ETS exposure in gene × environment interaction models.

METHODS

In 1995 and 1996 a cross sectional study was conducted in Munich and Dresden, Germany to assess the prevalence of asthma and allergies in schoolchildren aged 9–11 years as part of the worldwide effort to determine the prevalence of asthma and allergy during childhood. Parental questionnaires for self-completion including the ISAAC core questions were distributed through the schools to the parents to assess respiratory health and exposure to ETS. Children underwent skin prick testing, pulmonary function testing, and bronchial challenge with hyperosmolar saline (4.5%). Blood was obtained for serum IgE measurements and DNA extraction. Total serum IgE was measured in a 50% random sample of all the children who had given blood in Dresden and all children with blood available in Munich. In this study only children of German origin who had both DNA and IgE data available were included in the analysis (total N = 3099, Munich...
The study methods for all phenotyping procedures have been described in detail elsewhere. To test simultaneously for the presence or absence of GSTM1 and GSTT1 genes, a modified allele specific PCR assay described previously was used. Additional information on the applied methods for phenotyping and genotyping is available as supplementary online information on the Thorax website at www.thoraxjnl.com/supplemental.

Analysis of data

χ² statistics and Cochran-Armitage trend tests were used to compare qualitative traits between groups. Total serum IgE levels were summarised descriptively with geometric means and 95% confidence intervals. For binary outcomes, logistic regression models for gene × environment interactions were used to estimate the combined effect of either GSTM1 or GSTT1 with exposure to smoking in pregnancy and currently, adjusting for the effects of age, sex, city, and family history (asthma, atopic rhinitis, or atopic dermatitis). This analysis used the Botto-Khoury approach which summarises the data in a 2 × 4 table, enabling evaluation of the independent and combined roles of genotype and exposure on disease risk. The relative risk estimates for each factor alone and for the combined exposure are comparable because of the use of a common reference group. Additionally, the departure from the multiplicative model of interaction was derived from the table. Similarly, for continuous outcomes (lung function variables) a two way analysis of covariance (ANCOVA) was carried out to evaluate possible gene × environment interactions, also adjusting for the possible confounders mentioned above. With several outcomes, two genotypes, and two smoking exposures, the problem of multiple testing needed to be addressed. The Benjamini-Liu method controls the false discovery rate (FDR), a criterion described in Reiner et al within a predefined family of tests. We used the Benjamini-Liu multiple test correction with families for asthma, wheeze, treatment, and lung function for each smoking exposure and each genotype; within each family the FDR was controlled to either 1% or 5% (fig 1A and B).

All calculations were carried out using the SAS software package (version 8.2).

RESULTS

The study population successfully genotyped for this analysis consisted of 3054 subjects who were all of German nationality and origin. Of these, 1140 (37.3%) were from Munich, western Germany, and 1914 (62.7%) were from Dresden, eastern Germany. With respect to the prevalence of atopic diseases and the distribution of age, sex, and socioeconomic markers, the population from both areas did not differ from the subgroup which was not genotyped (data not shown). However, ETS exposure in utero as well as in the current household of the child was significantly more prevalent in Munich than in Dresden (in utero: 14.2% vs 4.4%; current ETS: 5.3% vs 2.0%).

The frequency of the GSTM1 null genotype was 51.6% (Munich 51.9%, Dresden 51.4%) and the frequency of the GSTT1 null genotype was 17.3% (Munich 16.3%, Dresden 17.8%). Double null genotypes (concomitant absence of both GSTM1 and GSTT1 alleles) occurred in 8.8% of the genotyped samples (Munich 7.8%, Dresden 9.4%). No statistically significant difference in allele frequency between the study populations from Munich and Dresden was detected. The allele distribution was within the range of previously reported allele frequency of GSTM1 and GSTT1 null alleles in other white populations. Furthermore, the distribution of genotypes in the population did not deviate from the expected Hardy-Weinberg equilibrium.

We did not detect a major effect of GSTM1 or GSTT1 null genotypes per se on the prevalence of asthma, asthma symptoms, wheezing, or other atopic diseases in our unstratified population sample of German children (table E1, online supplement). Furthermore, no effect of a double null GST genotype on the prevalence of atopic diseases was observed (data not shown). For the development of childhood asthma a gene × gene interaction model based on GSTM1 and GSTT1 was rejected (data not shown).

When a combined analysis of smoke exposure and GSTM1 genotypes was performed, a significantly increased risk of developing asthma, asthma symptoms, and wheezing was apparent in children who had a GSTM1 or GSTT1 null genotype and were also exposed to current ETS (tables 1 and 2). In children with a GSTM1 null genotype exposed to current ETS the increased risk was statistically significant for all wheeze outcomes as well as for current asthma. For children with a GSTT1 null genotype exposed to current ETS, odds ratios (ORs) similar to those found in GSTM1 were observed. However, as the gene frequency was lower, confidence intervals were wider and the trends were not always statistically significant. In tables 1 and 2, expected
ORs for the combined effects of ETS exposure and GSTM1/GSTT1 deficiency are shown as well as departures from the expected OR for multiplicative interaction (column 5). As shown in table 1, the effect of the GSTM1 null genotype without ETS exposure was only marginal, while exposure to ETS alone increased the risk for current asthma and asthma symptoms regardless of the GSTM1 genotype. A combined statistically significant effect of the GSTM1 null genotype and ETS exposure was observed compared with children with no ETS exposure and no GSTM1 deficiency (column 4), with several variables showing a positive departure from the expected OR for multiplicative interaction. However, this departure did not reach statistical significance, thus only hinting at a possible interaction (column 5). Exposure to in utero ETS combined with a GSTM1 null genotype showed a trend for an increased risk without reaching statistical significance, while the combination of a GSTT1 null genotype and in utero ETS showed no obvious pattern (tables E2 and E3, online supplement). In the analysis of current smoke exposure and GST genotype, asthma symptoms increased with the amount of current smoke exposure with the strongest effect being observed in children exposed to more than 20 cigarettes smoked in the household (data not shown).

In a further analysis the combined effect of current or in utero ETS exposure and GST genotypes on lung function measurements was studied (fig 1A and B). In utero ETS exposure combined with the GSTT1 null genotype showed the strongest effect on lung function measurements (fig 1A). All other lung function measurements showed small to very large decreases in the GSTT1 negative subgroup exposed to ETS in utero. After correction for multiple testing, a statistically significant interaction between ETS exposure and GSTT1 deficiency was observed for the MEF25 and MMEF measurements. The GSTM1 null genotype and in utero ETS exposure showed a weaker combined effect on lung function (fig 1B), statistically significant only in its effect on MMEF. Current ETS exposure combined with GSTT1 deficiency did not decrease lung function measurements in our study population (data not shown).

### DISCUSSION

This study has genotyped the largest population to date for polymorphisms in GSTT1 and GSTM1. In contrast to previous studies, all 3054 eligible study subjects were white and of German nationality and origin. Population stratification is therefore very unlikely to have influenced the findings. The population was carefully phenotyped for asthma and allergic symptoms.

#### Table 1

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>(1) GSTM1− and ETS−</th>
<th>(2) GSTM1− and ETS+</th>
<th>(3) GSTM1− and ETS−</th>
<th>(4) GSTM1− and ETS−</th>
<th>(5) Expected OR/departure from expected OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current asthma</td>
<td>3.9 (29/735)</td>
<td>6.1 (2/33)</td>
<td>5.1 (39/758)</td>
<td>8.9 (4/45)</td>
<td></td>
</tr>
<tr>
<td>Wheeze ever</td>
<td>19.6 (142/725)</td>
<td>24.2 (8/33)</td>
<td>23.0 (172/748)</td>
<td>31.1 (14/45)</td>
<td></td>
</tr>
<tr>
<td>Current wheeze</td>
<td>6.5 (47/726)</td>
<td>9.1 (3/33)</td>
<td>8.9 (67/749)</td>
<td>17.8 (8/45)</td>
<td></td>
</tr>
<tr>
<td>Current cough</td>
<td>15.5 (113/727)</td>
<td>12.1 (4/33)</td>
<td>15.5 (117/753)</td>
<td>26.1 (12/45)</td>
<td></td>
</tr>
<tr>
<td>without cold</td>
<td>1.0</td>
<td>1.0 (0.34 to 3.18)</td>
<td>1.0 (0.78 to 1.37)</td>
<td>2.76 (1.23 to 6.17)</td>
<td></td>
</tr>
</tbody>
</table>

In each cell the prevalence (%) of each outcome is shown with numbers of cases and total in parentheses. Adjusted odds ratio (OR) with 95% confidence intervals, adjusted for age, sex, city, family history of asthma, hay fever, eczema and ETS exposure, are compared with the reference cell (second line of each cell). Column 5 shows the expected effect of GSTM1 and current ETS exposure combined with the GSTT1 null genotype with the strongest effect being observed in respiratory symptoms, while the combination of a GSTM1 null genotype and current ETS exposure showed the strongest effect on lung function measurements (fig 1A). All other lung function measurements showed small to very large decreases in the GSTT1 negative subgroup exposed to ETS in utero. After correction for multiple testing, a statistically significant interaction between ETS exposure and GSTT1 deficiency was observed for the MEF25 and MMEF measurements. The GSTM1 null genotype and in utero ETS exposure showed a weaker combined effect on lung function (fig 1B), statistically significant only in its effect on MMEF. Current ETS exposure combined with GSTT1 deficiency did not decrease lung function measurements in our study population (data not shown).

#### Table 2

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>(1) GSTT1− and ETS−</th>
<th>(2) GSTT1− and ETS+</th>
<th>(3) GSTT1− and ETS−</th>
<th>(4) GSTT1− and ETS−</th>
<th>(5) Expected OR/departure from expected OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current asthma</td>
<td>4.8 (59/1238)</td>
<td>7.5 (5/67)</td>
<td>3.5 (9/255)</td>
<td>9.1 (1/11)</td>
<td></td>
</tr>
<tr>
<td>Wheeze ever</td>
<td>21.8 (266/1222)</td>
<td>25.4 (17/67)</td>
<td>19.1 (48/251)</td>
<td>45.5 (5/11)</td>
<td></td>
</tr>
<tr>
<td>Current wheeze</td>
<td>7.9 (96/1222)</td>
<td>1.77 (0.92 to 3.42)</td>
<td>0.84 (0.60 to 1.19)</td>
<td>4.37 (1.17 to 16.39)</td>
<td></td>
</tr>
<tr>
<td>Current cough</td>
<td>15.4 (189/1228)</td>
<td>16.2 (11/68)</td>
<td>16.3 (41/252)</td>
<td>42.5 (6/11)</td>
<td></td>
</tr>
<tr>
<td>without cold</td>
<td>1.0</td>
<td>1.50 (0.71 to 3.20)</td>
<td>1.08 (0.74 to 1.56)</td>
<td>6.72 (1.77 to 25.52)</td>
<td></td>
</tr>
</tbody>
</table>

In each cell the prevalence (%) of each outcome is shown with numbers of cases and total in parentheses. Adjusted odds ratio (OR) with 95% confidence intervals, adjusted for age, sex, city, family history of asthma, hay fever, eczema and ETS exposure, are compared with the reference cell (second line of each cell). Column 1 shows the reference group without smoke exposure and without genetic defect in the respective GST enzyme; column 2 shows the effect of GSTT1 deficiency and concomitant ETS exposure; column 3 shows the isolated effect of ETS exposure in children with the intact GST gene, respectively; column 4 shows the values for the combined effect of the respective GST deficiency and concomitant ETS exposure; column 5 shows the expected OR under the assumption of a multiplicative effect, the departure from the effect, and the statistical significance of the departure from the multiplicative model. *p value <0.05 compared with reference group. †Departure from expected OR = OR in column 4 divided by the expected OR. ‡Expected OR is the product of the ORs in columns 2 and 3.
traits according to the international standards of the ISAAC study protocols, and the validity of questionnaire derived phenotypes has been shown previously. The exposure of children to ETS in the home was assessed by self-administered parental questionnaires shown to be a valid tool for measuring ETS exposure.

When ETS exposure was not included in the analysis, neither GSTM1 nor GSTT1 deficiency had an effect on the development of asthma in this population (table E1, online supplement). These findings indicate that the environmental exposure to toxic substances is necessary to unravel the effect of the genetically determined deficiencies in GST dependent detoxification processes. In GSTM1 deficient children exposed to ETS, odds ratios for current asthma, wheezing phenotypes, and current cough were significantly increased while, for GSTT1 deficient children exposed to ETS, only wheeze ever and current cough reached statistical significance. When interaction models were applied as shown in the Botto-Khoury tables, an overall trend for a positive effect was found, mostly over and above the expected multiplicative interaction between GSTM1 and GSTT1 deficiency and ETS exposure. Even though the observed combined ORs deviated consistently from expected multiplicative models, the deviation above the expected multiplicative OR did not reach statistical significance. This may largely be the result of the relatively small number of subjects in the high risk groups, even though more than 3000 subjects were initially included and genotyped in this project. Power calculations indicate that, based on our baseline disease prevalence rates, between 2.7 and 48 times more individuals would have been necessary to reach statistical significance for all the observed interaction effects. However, the statistically suggested interaction between ETS exposure and GSTM1 deficiency constantly shown in our data adds to the plausibility of a biological interaction between GST enzymes and components of ETS in the detoxification process. Experimental data support these epidemiological observations: In the lung tissue of GSTM1 deficient individuals higher levels of aromatic DNA adducts have been found, and cytogenetic damage to lung cells caused by smoke exposure increases with GSTM1 deficiency. This indicates increased damage to DNA and the destruction of tissue due to diminished GSTM1 function. Also, GSTT1 negative individuals have been found to have significantly higher levels of DNA damage than GSTT1 positive individuals in experimental in vitro settings. Furthermore, recent data indicate that GSTM1 may modify the adjuvant effect of diesel exhaust particles on allergic inflammation.

Our findings suggest that the strongest effect on the development of asthma and asthma symptoms occurs in GSTM1 and GSTT1 deficient individuals currently exposed to ETS. However, a small non-significant effect of in utero smoke exposure in GSTM1 deficient children on the occurrence of asthma and asthma symptoms was also observed in this population (tables E2 and E3, online supplement). In contrast to our findings, Gilliland and coworkers reported a major effect of in utero ETS exposure on asthma and asthma symptoms in GSTM1 negative individuals in their population of children from the US, whereas current ETS exposure showed only a non-significant increase in asthma and wheeze. The combination of these findings indicates that GST negative individuals are at a higher risk of developing asthma and asthma symptoms which could be the result of in utero as well as current ETS exposure. As both exposures are interconnected, our analyses for the effects of in utero ETS exposure were adjusted for current ETS exposure and vice versa. Both types of ETS exposure showed independent effects on respiratory health in GSTM1 negative individuals in our analysis, but were only significant for current passive smoking where a trend for a dose dependent effect was observed (data not shown). Unfortunately, children heavily exposed to ETS in utero could not be identified in our study as the extent of active and passive smoking of mothers during pregnancy was not assessed.

Evidence exists that smoking during pregnancy affects the growth of the fetus and the maturation of the fetal lung, resulting in an impairment of lung function in the newborn. Furthermore, previous studies have suggested that GSTM1 deficient children may have impaired lung function growth. Our results suggest, however, that pulmonary function is only affected in exposed subjects with a GSTT1 deficiency. Interestingly, small airways were affected most while forced expiratory volume in 1 second measurements remained unaffected. As shown previously, early deficits in small airway function may predispose children to transient wheezing later in life. Our data allowed us to define different wheezing phenotypes retrospectively. Only wheezing persisting from infancy to school age was associated with GSTT1 deficiency and ETS exposure (data not shown), which suggests that small airway size may contribute to the development of asthma. Since prevalence is determined by incidence and duration of an illness, we cannot discriminate whether the observed effects relate more to the severity or to the incidence of asthma. While ETS exposure is a serious health hazard for children in the general population, some are even more susceptible to developing asthma and more severe asthma symptoms when exposed to passive smoking. GST deficiency and other genetic alterations in detoxification pathways not yet studied may add to the adverse health effects caused by passive and active tobacco smoking which should be further investigated in large population samples.

Additional information is available as supplementary online information on the Thorax website at www.thoraxjnl.com/supplemental.

Authors’ affiliations
M Kabesch, C Hoeffler, D Carr, E von Mutius, University Children’s Hospital Munich, Germany
W Leupold, University Children’s Hospital Dresden, Germany
S K Weiland, Institute of Epidemiology, University of Ulm, Germany
This study was funded by the German Ministry of Education and Research as part of the German national genome research network, grant GS 01 0122. MK was also funded by the carrier development grant R186 from the University of Munich.

REFERENCES
LUNG ALERT

Improved survival with postoperative uracil-tegafur in stage 1 adenocarcinoma of the lung


Tegafur is a pro-drug that is converted to fluorouracil, and the serum concentration of fluorouracil is enhanced by uracil. While fluorouracil itself has no apparent effect on survival in non-small cell lung cancer, Japanese studies of uracil-tegafur have reported a mortality benefit when used as an adjuvant therapy. In subgroup analysis this benefit was confined to adenocarcinoma.

The present study randomised patients to receive oral uracil-tegafur (250 mg/m²/day, n = 491) or no treatment (n = 488) for 2 years following resection of stage 1 (T1M0N0 or T2M0N0) adenocarcinoma of the lung. Despite being an open label study, it was well planned and adequately powered. Median follow up was 73 months. Overall there was a statistically significant survival advantage favouring treatment (p = 0.04) with a 5 year survival of 88% (CI 85 to 91) compared with 85% (CI 82 to 89). On subgroup analysis this difference was only apparent in those patients with T2 disease: 5 year survival with treatment was 85% (CI 79 to 91) compared with 74% without (CI 66 to 81). There were few serious drug related adverse events but only 61% of patients completed the 2 year treatment period.

This study shows a survival advantage for postoperative adjuvant oral uracil-tegafur in stage 1 (T2) adenocarcinoma of the lung.

M H Lawson
Senior House Officer, St Bartholomew’s Hospital, London, UK;
mhlawson@tregarvonroad.fsnet.co.uk